ALEXANDRA GLOBAL MASTER FUND LTD

Form SC 13G/A February 14, 2007

> SCHEDULE 13G CUSIP NO. 150934107

PAGE 1 OF 9 PAGES

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)*

Cell Therapeutics, Inc. (Name of Issuer)

Common Stock, no par value (Title of Class of Securities)

150934107 (CUSIP Number)

December 31, 2006 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- | | Rule 13d-1(b)
- |X| Rule 13d-1(c)
- | | Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G CUSIP NO. 150934107

PAGE 2 OF 9 PAGES

1 NAME OF REPORTING PERSON

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

Alexandra Global Master Fund Ltd. 98-0448776

2 CHECK THE APP:	ROPRIATE BOX IF A MEMBER OF A GROUP (A) (B) (See Item 6	
3 SEC USE ONLY		
4 CITIZENSHIP O	R PLACE OF ORGANIZATION	
Brit	ish Virgin Islands	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	5 SOLE VOTING POWER	
	-0-	
	6 SHARED VOTING POWER	
	1,065,036 shares of Common Stock (See Item 4)	
	7 SOLE DISPOSITIVE POWER	
	-0-	
	8 SHARED DISPOSITIVE POWER	
	1,065,036 shares of Common Stock (See Item 4)	
	IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES HARES (SEE INSTRUCTIONS)	
11 PERCENT O	F CLASS REPRESENTED BY AMOUNT IN ROW (9)	
0.7%	(See Item 4)	
12 TYPE OF R	OF REPORTING PERSON (SEE INSTRUCTIONS)	
CO		
HEDULE 13G SIP NO. 150934107	PAGE 3 OF 9 PA	
1 NAME OF REPOR	TING PERSON FICATION NO. OF ABOVE PERSON (ENTITIES ONLY)	
	andra Investment Management, LLC 092583	
2 CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP (A) (B) (See Item 6	

4 CITIZENSHIP OR F	PLACE OF ORGANIZATION			
Delawar	re 			
NUMBER OF SHARES	5 SOLE VOTING POWER			
BENEFICIALLY OWNED BY -				
EACH REPORTING	6 SHARED VOTING POWER			
PERSON	1,065,036 shares of Common Stock (See	Item 4)		
WITH:	7 SOLE DISPOSITIVE POWER			
	-0-			
	8 SHARED DISPOSITIVE POWER			
	1,065,036 shares of Common Stock (See	Item 4)		
9 AGGREGATE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING	PERSON		
1,065,	036 shares of Common Stock (See Item 4)			
	T THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES RES (SEE INSTRUCTIONS)	1 1		
11 PERCENT OF C	CLASS REPRESENTED BY AMOUNT IN ROW (9)			
0.7% (5	See Item 4)			
12 TYPE OF REPO	ORTING PERSON (SEE INSTRUCTIONS)			
00				
EDULE 13G				
IP NO. 150934107	PAGE	C 4 OF 9 PAG		
1 NAME OF REPORTIN	NG PERSON CATION NO. OF ABOVE PERSON (ENTITIES ONLY)			
Mikhail	A. Filimonov			
2 CHECK THE APPROP	PRIATE BOX IF A MEMBER OF A GROUP (A) (B)	See Item 6		
		ONLY		
3 SEC USE ONLY				

	U.S.	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		SOLE VOTING POWER
		SHARED VOTING POWER
		1,065,036 shares of Common Stock (See Item 4)
		SOLE DISPOSITIVE POWER
		-0-
	8	SHARED DISPOSITIVE POWER
		1,065,036 shares of Common Stock (See Item 4)
9 AG0	 GREGATE AMOUN	T BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1,065,036	shares of Common Stock (See Item 4)
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
11 PEF	RCENT OF CLAS	SS REPRESENTED BY AMOUNT IN ROW (9)
	0.7% (See	Item 4)
12 TYE	PE OF REPORTI	ING PERSON (SEE INSTRUCTIONS)
	IN	
SCHEDULE 13G CUSIP NO. 150934107		PAGE 5 OF 9 PAGES
Item 1(a).	Name of I	ssuer:
	Cell Ther "Issuer")	rapeutics, Inc., a Washington corporation (the
Item 1(b).	Address o	of Issuer's Principal Executive Offices:
		ott Avenue West, Suite 400 Washington 98119
Item 2(a).	Names of	Persons Filing:
	Alexandra	a Global Master Fund Ltd. ("Alexandra") a Investment Management, LLC ("Management") a. Filimonov ("Filimonov")
Item 2(b).	Address o	of Principal Business Office:
	Road Towr Managemer New York	a - Citco Building, Wickams Cay, P.O. Box 662, n, Tortola, British Virgin Islands nt - 767 Third Avenue, 39th Floor, New York, 10017 y - 767 Third Avenue, 39th Floor, New York,

New York 10017

Item 2(c). Place of Organization or Citizenship:

Alexandra - British Virgin Islands

Management - Delaware
Filimonov - U.S.

Item 2(d). Title of Class of Securities:

Common Stock, no par value per share, of the Issuer (the

"Common Stock")

Item 2(e). CUSIP Number: 150934107

Item 3. This Schedule is filed pursuant to Rule 13d-1(c) by

Alexandra, Management and Filimonov

Item 4. Ownership:

(a) Amount Beneficially Owned:

Alexandra: 1,065,036 shares*
Management: 1,065,036 shares*
Filimonov: 1,065,036 shares*

(b) Percent of Class:

Alexandra: 0.7%*
Management: 0.7%*
Filimonov: 0.7%*

(Based on 144,652,751 shares of Common Stock outstanding, as of October 31, 2006, as reported by the Issuer in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2006)

(c) Number of Shares as to which the Person has:

SCHEDULE 13G CUSIP NO. 150934107

PAGE 6 OF 9 PAGES

(i) sole power to vote or to direct the vote

-0-

(ii) shared power to vote or to direct the vote:

1,065,036 shares of Common Stock*

(iii) sole power to dispose or to direct the

 $\hbox{\tt disposition of}$

-0-

(iv) shared power to dispose or to direct the

disposition of

1,065,036 shares of Common Stock*

The shares of Common Stock reported as beneficially owned by Alexandra on this Schedule are 1,065,036 shares of Common Stock that Alexandra has the right to acquire upon conversion of 6.75% Convertible Senior Notes Due 2010 of the Issuer.

Management serves as investment advisor to Alexandra. By reason of such relationship, Management may be deemed to share voting and dispositive power over the shares of Common Stock owned by Alexandra. Management disclaims beneficial ownership of the shares of Common Stock listed as beneficially owned by Alexandra or any other person reporting on this Schedule.

Filimonov serves as the Chairman, the Chief Executive Officer, a Managing Member and the Chief Investment Officer of Management. By reason of such relationships, Filimonov may be deemed to share voting and dispositive power over the shares of Common Stock listed as beneficially owned by Management. Filimonov disclaims beneficial ownership of the shares of Common Stock listed as beneficially owned by Management or any other person reporting on this Schedule.

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the class of securities, check the following $|\mathsf{X}|$

Not applicable

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

Not applicable

Item 8. Identification and Classification of Members of the Group:

SCHEDULE 13G CUSIP NO. 150934107

PAGE 7 OF 9 PAGES

Not applicable

Item 9. Notice of Dissolution of Group:

Not applicable

Item 10. Certification:

By signing below each signatory certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Exhibits:

Exhibit I: Joint Filing Agreement, dated as of February 14, 2007, by and among Alexandra, Management and Filimonov.

SCHEDULE 13G CUSIP NO. 150934107

PAGE 8 OF 9 PAGES

SIGNATURE

By signing below each signatory certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Dated as of February 14, 2007

ALEXANDRA GLOBAL MASTER FUND LTD.

By: ALEXANDRA INVESTMENT MANAGEMENT, LLC, its Investment Advisor

By: /s/ Mikhail A. Filimonov
----Mikhail A. Filimonov
Title: Managing Member

ALEXANDRA INVESTMENT MANAGEMENT, LLC

By: /s/ Mikhail A. Filimonov
----Mikhail A. Filimonov
Title: Managing Member

/s/ Mikhail A. Filimonov
----Mikhail A. Filimonov

SCHEDULE 13G CUSIP NO. 150934107

PAGE 9 OF 9 PAGES

Exhibit I

JOINT FILING AGREEMENT

This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, no par value, of Cell Therapeutics, Inc., a Washington corporation, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated as of February 14, 2007

ALEXANDRA GLOBAL MASTER FUND LTD.

By: ALEXANDRA INVESTMENT MANAGEMENT, LLC, its Investment Advisor

By: /s/ Mikhail A. Filimonov
----Mikhail A. Filimonov
Title: Managing Member

ALEXANDRA INVESTMENT MANAGEMENT, LLC

By: /s/ Mikhail A. Filimonov
----Mikhail A. Filimonov
Title: Managing Member

/s/ Mikhail A. Filimonov
----Mikhail A. Filimonov